Oxidative Stress Markers in COPD

February 9, 2021 updated by: zainab hassan saeed, Minia University

Chronic Obstructive Pulmonary Disease in Non Smokers:Role of Oxidative Stress

Background:Striking feature of Chronic obstructive pulmonary disease (COPD) is its inability to resolve after cigarette smoke exposure has ended, which has contributed to the possibility that the disease could also be driven by other endogenous causes, such as autoimmunity or chronic infection . Many of the pathogenetic pathways involved in COPD and its development tend to be driven by oxidative stress.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

70

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
    • Minia
      • Multiple Locations, Minia, Egypt, 61691
        • Minia university hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Forty subjects of COPD who are non-smokers or stopped smoking for more than 6 months Based on the Global Initiative for Chronic Obstructive Lung Disease guidelines, COPD was diagnosed.9 2- Thirty subjects of non smokers healthy control

Description

Inclusion Criteria:

  • 1-Forty subjects of COPD who are non-smokers or stopped smoking for more than 6 months Based on the Global Initiative for Chronic Obstructive Lung Disease guidelines, COPD was diagnosed.9 2- Thirty subjects of non smokers healthy control

Exclusion Criteria:

  • Patients of:

    1. Acute exacerbation, at the time of the study, of COPD.
    2. Any obvious abnormal lung parenchymal lesions.
    3. Lung cancer.
    4. Congestive heart failure.
    5. current smokers
    6. Drugs e.g anti-inflammatory , steroids ,analgesics, insulin , antineoplastic, antipsychotic drugs in the previous 2 weeks before the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
nonsmokers copd cases ,
Fourty subjects of COPD who are non-smokers or stopped smoking for more than 6 months
Other: oxidative stess markers
markers of oxidative stress , Superoxide Dismutase (SOD) and Malondialdehyde (MDA) by ( ELISA Kit SinoGeneClon Biotech Co.,Ltd Catalog No : SG- 10188) .
Other Names:
  • Superoxide Dismutase (SOD) and Malondialdehyde (MDA)
non smokers healthy control
Thirty subjects of non smokers healthy control
Other: oxidative stess markers
markers of oxidative stress , Superoxide Dismutase (SOD) and Malondialdehyde (MDA) by ( ELISA Kit SinoGeneClon Biotech Co.,Ltd Catalog No : SG- 10188) .
Other Names:
  • Superoxide Dismutase (SOD) and Malondialdehyde (MDA)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
oxidative stress markers in non smokers COPD compared to healthy control
Time Frame: 1month
markers of oxidative stress , Superoxide Dismutase (SOD) and Malondialdehyde (MDA) by ( ELISA Kit SinoGeneClon Biotech Co.,Ltd Catalog No : SG- 10188) .
1month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Minia University

Investigators

  • Principal Investigator: zainab H Saeed, MD, MD chest diseases

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2018

Primary Completion (Actual)

April 1, 2019

Study Completion (Actual)

September 1, 2019

Study Registration Dates

First Submitted

February 5, 2021

First Submitted That Met QC Criteria

February 9, 2021

First Posted (Actual)

February 10, 2021

Study Record Updates

Last Update Posted (Actual)

February 10, 2021

Last Update Submitted That Met QC Criteria

February 9, 2021

Last Verified

February 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • oxidative stress

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe